Sign up to save your podcasts
Or
Share The FirstTake Podcast – Gilead’s oncology strategy under the spotlight
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The FirstTake Podcast – Gilead’s oncology strategy under the spotlight
On this week’s episode FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss why Gilead is getting flak for a positive cancer drug study, what’s gone wrong at bluebird bio and why the FDA has been so quick to expand approval of Bristol Myers Squibb’s Opdivo for the treatment of neoadjuvant lung cancer.
View all episodes
By FirstWord PharmaOn this week’s episode FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss why Gilead is getting flak for a positive cancer drug study, what’s gone wrong at bluebird bio and why the FDA has been so quick to expand approval of Bristol Myers Squibb’s Opdivo for the treatment of neoadjuvant lung cancer.